Clinical trials: Multiple Sclerosis-Relapsing-Remitting
Multiple Sclerosis
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT01767493
- Testing
- [18F]Florbetapir PET imaging
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple…
- Trial name
- CLOCK-MS (NCT03963375)
- Testing
- Cladribine
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Gregory Wu
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects' participation of 48 weeks.
- Trial name
- Antelope (NCT04115488)
- Testing
- Intravenous (IV) infusions
- Where
- 48 sites in Belarus, Croatia and 5 more
- Volunteers
- 265 people
- Sponsor
- Polpharma Biologics S.A.
Multiple Sclerosis, Relapsing-Remitting
Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)
This study will enroll about 66 participants who experienced a relapse of RRMS that steroids did not help. The doctor will put participants into a treatment group.
- Trial name
- OPTIONS (NCT03126760)
- Testing
- Acthar Gel
- Where
- 22 sites in United States
- Volunteers
- 35 people
- Sponsor
- Mallinckrodt ARD LLC
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
The study will assess the long-term safety and tolerability of AIN457 in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01433250
- Testing
- AIN457
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis.
- Trial name
- NCT00662649
- Testing
- Fingolimod 0.5 mg, Fingolimod 1.25 mg
- Where
- 103 sites in Australia, Belgium and 20 more
- Volunteers
- 920 people
- Sponsor
- Novartis
Relapsing Remitting Multiple Sclerosis
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
The primary objective of this study was to assess the bioequivalence of the test product (Bafiertam; BLS-11; monomethyl fumarate) 190 mg versus Tecfidera® (dimethyl fumarate) 240 mg based on the Cmax and Area Under the Curve…
- Trial name
- NCT04570670
- Testing
- monomethyl fumarate 190 mg, dimethyl fumarate 240 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Relapsing Remitting Multiple Sclerosis
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI…
- Trial name
- OCTAVE (NCT03157830)
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three…
- Trial name
- MoveS-it (NCT04602390)
- Testing
- ANK-700
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Anokion SA
Relapsing-remitting Multiple Sclerosis
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod.
- Trial name
- NCT02720107
- Testing
- fingolimod
- Where
- 26 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects with relapsing-remitting multiple…
- Trial name
- RECYCLINE (NCT01134627)
- Testing
- Minocycline
- Where
- Denmark
- Volunteers
- 305 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis…
- Trial name
- EXTEND (NCT01797965)
- Testing
- BIIB019 (Daclizumab)
- Where
- 222 sites in United States, Argentina and 25 more
- Volunteers
- 1,501 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg…
- Trial name
- NCT01185821
- Testing
- BAF312
- Where
- 46 sites in United States, Canada and 10 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
- Trial name
- START (NCT01585298)
- Testing
- FTY720
- Where
- 258 sites in Germany
- Volunteers
- 6,998 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
The purpose of this study is to determine whether raltegravir is effective in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced MRI.
- Trial name
- INSPIRE (NCT01767701)
- Testing
- Raltegravir
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple…
- Trial name
- NCT00246324
- Testing
- Interferon beta 1a, oral doxycycline
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Multiple Sclerosis
Assessing Tolerability of Avonex Intramuscular Injections
The purpose of this study is to evaluate patients' views when injecting Avonex intramuscularly.
- Trial name
- NCT01641120
- Testing
- Avonex
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Trinity Health Of New England
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted…
- Trial name
- NCT02545868
- Testing
- 23-PPV, 13-PCV Booster, Influenza Vaccine
- Where
- 22 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
The primary objective of this study was to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) participants with relapse.
- Trial name
- NCT00803049
- Testing
- Teriflunomide (HMR1726)
- Where
- 116 sites in United States, Austria and 19 more
- Volunteers
- 742 people
- Sponsor
- Sanofi
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche